To assess the use of adenosine as an alternative agent for deter mination of coronary vasodilator reserve, hemodynamics and coronary blood flow velocity were measured at rest and during peak hyperemic responses to continuous intravenous adenosine infusion 1511, 100 and 150 pg/kg per min for 3 min) and intracor onary papaverine (IO mg) in 34 patients (17 without [group 11 and 17 with [group 21 significant left coronary artery disease), and in 17 patients (11 without and 6 with left coronary artery disease) after low dose (2 .5 mg) intravenous bolus injection of adenosine.
flow velocity) for adenosine and papaverine was 2 .94 ± 1 .50 and 2.94 ± 1 .00, respectively, in group I and was significantly and similarly reduced in group 2 (2.16 ± 0.81 and 2.38 ± 0,78, respectively; both p < 0 .05 vs, group 1). Low dose bolus injection of adenosine ilxreased mean velocity equivalently to that after continuous infusion of 100 pg/kg, but less than after papaverine. There was a strong correlation between adenosine infusion and papaverine for both mean coronary flow velocity and coronary vasaditntor reserve ratio (r r = 0 .871 and 0.325; SEE = 0 .068 and 0 .189, respectively ; both p < 0,0005).
No patient had significant arrhylhmias or prolongation of the corrected QT (QTc) interval with adenosine, but papaverine increased the QTc interval from 445 t 44 to 501 t 43 ms p < 0 .001 vs. both maximal adenosine and baseline) and produced nonsustained ventricular taehycardia in one patient .
These data indicate that intravenous adenosine in doses > 100 jug/kg (and in low dose bolus injections) for most patients is nearly equivalent to intracoronary papaverine without producing QTc prolongation, making this agent a potentially superior and safer alternative to inD acoronary papaverine for determination of coronary vasodilator reserve.
/d Am Cull Cnrdiel 1991;18x718 29) of severe ventricular arrhythm ;as requiring immediate car dioversion (5 8) , alternative pharmacologic stimuli for cor onary vasodilator reserve are dasfroble . Intracoronary aden osine has been used recently (9 .10) and induces maximal coronary hyperemia similar to that of intracoronary papav erine (4) . However, the induction of complete heart block and severe bradycardia with a variable dose response re ported in earlier studies (9f has limited wide application of intracoronay adenosine . Conversely, intravenous adeno sine also produces significant if not equi"alent hyperemia comparable with that of other coronary vasodilators but without QT prolongation or heart block in doses <200 pg/kg body weight (11 13) . Compared with dip, ridamole, intrave nous adenosine has an additional advantage of being a very short acting drug . Prominent but transient side effects of facial flushing and chest discomfort resolve within seconds of termination of adenosine infusion (14) .
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This study tested the hypothesis that coronary hyperemia induced by intravenous infusion or bolus injection of aden osine would he equivalent to that produced byintracoronorv papaverine without QT prolongation ar induct or of sign, heart conduction disturbances . These dirt anuld provide the basis fur use of this agent in patients with a high likeli hood of an adverse response to intracuronary papaverine ur in whom an intravenous rather than intracoronarv drue administration for hyperemia stimtiialion would hc dcSir able . were given orally as routine precalheterization medications to all patients . No sublingual or intracoronary medications were given until the initiation of the study ; heparin . 5.000 U . was given intravenously after insertion of the coronary catheters. The research protocol was approved by the Hu man Subjects Committee of the Institutional Review Board at St . Louis University Hospital . All patients gave informed written consent in accordance with guidelines established by the Human Subjects Committee .
Erpc'rirneatal Protocol
The study protocol was designed to measure coronary blood flow velocity responses to intracoronary papaverine and three doses of adenosine administered by continuous intrave nous infusion and intravenous low dose bolus injection .
Coronary blood flow velocity, measurements . After diag nostic coronary angiography and left ventriculography, cor onary blood flow velocity was measured with use of an 8F Judkins style Doppler catheter lCordis Corporation) with a 20 MHz Doppler crystal implanted in the lip as previously described and validated (I5) . 5nis nonselective intracoro . nary velocity catheter was used in all but two patients it whom whselective intracoronary flow velocity was mea sured with a 3F Doppler catheter (DC 101 . Millar Instru ments) 13). The Doppler catheter was positioned within a proximal normal left coronary artery segment before the large branch bifurcation, This location was maintained con slant throughout the study period . Doppler data were proc essed with a zero cross velocimeter (Millar Instruments) from which mean and phasic velocity signals were obtains . The Doppler coronary flow velocity and hemodynamic sig nals were displayed and recorded on a photographic multi channel oscillographic recorder (Electronics for Medicine, VR12) . Mean and phasic Doppler velocity signals were calibrated front the velocimeter before catheter placement from an internally set arbitrary 0 to 100 cmls signal for full scale deflection .
After stable baseline signals were obtained, 10 mg of tICC set IS . Nn . I ScnICmFcr 199101K 29 papaverine was injected into the left coronary artery over I to ' s with continuous data recording through the peak hyperemic period and for 60 to 120 s later . In 10 patients. after return to the control state . a second duplicate to to 12 mg papaverine injection was also performed . After ?3 min of equilibration to baseline values, adenosine (5 mg'ml. AB Hassle) was infused into the femoral vein by a controlled pump (Harvard Apparatus) to deliver 50, 100 and 150 µg/kg body weight per min . each dose given over 3 min . Data were recorded al the end of each dosing interval, after which the next dose was initiated. The time to onset of hyperemia and offset of maximal hyperemia was recorded . The order of adenosine and papaverine administration was reversed in 18 patients . In 17 patients (11 in group I and 6 in group 2), a 2 .5 mg bolus injection of adenosine was given through a femoral (n = 14) or brachial (n 3) vein . with continuous hemody namic data recording . A second bolus dose of 5 mg was given in nine patients . In 19 patients (8 in group I and I1 in group 2) . pulmonary artery pressures were measured during coronary hyperemia with a fluid filled balloon tipped cathe ter positioned from a femoral vein .
In 30 patients, a 12 lead electrocardiogram (ECG) was obtained al baseline and at peak hyperemia for each dose of adenosine and papaverine . From the 12 lead ECG obtained at rest and at peak hyperemia, the QT interval was measured and corrected with Bazett's formula . An ST segment depres sion was reported when the ST segment shift was >0 .5 mV from baseline . New T wave inversion or T wave flattening occurred in two patients. The duration of second degree heart block was measured from the continuous lead II ECG recording during hemodynamic data collection .
Coronary angiographic measurements . To assess changes in coronary dimension during adenosine infusion, a left coronary cineangiogram (20' right anterior oblique projec tion) was obtained at baseline and at peak hyperemia in 10 patients . The developed cineangiographic films were pro jected on a General Electric CAP 12 projector. Digital com puter assisted calipers (Sandhill Scientific) were used to measure the arterial segment 5 to 10 mm distal to the velocity catheter tip and in the mid left anterior descending artery distal to the circumflex artery bifurcation . The BE velocity catheter diameter (2 .67 mm) was used as a scale factor for absolute dimension calculations in millimeters . Angiography was not performed during papaverine induced hyperemia. Overestimation of vasodilator reserve of approx imately 169'e with papaverine induced vessel diameter en largement has been previously reported (16) .
Coronary velocity signal analysis. Coronary artery veloc ity signals, both phasic and mean, were recorded at both a IP and a 100 mm's paper speed and digitized on an off line microcomputer system . The diastolic flow velocity integral svos obtained by planimetry of the area under the diastolic velocity signal from the aortic dicrotic notch to the systolic aortic upstroke as previously reported (171 . The total time of diastolic flow velocity and time to maximal phasic flow velocity were also measured .
Coronary vasodilator reserve ratios. The coronary vaso dilator reserve ratio was computed as the ratio of peak hyperemic flow to basal mean flow velocity . A coronary artery resistance index was computed as the quotient of mean arterial pressure and mean coronary velocity . An additional index of coronary vasmlilalor response normalized for mean arterial Data presented in the subset of 17 patients all receiving adenosine infusion, adenosine bolus injection and papaverine :9of the 17 patients received a second bolosinjeclionof5ntgofadenosine,'p00.05versusbzseline:Act) =adnr inlraven0usinfusionD0004(68permin) :A2 .S=adcnasiueinlnvenousbolus injectoo 12 .5 mgt : A5 = adenosine intravenous bolus injection IS mgt . CVR soronary vasodilarnr reserve ratio : DVF, = diastolic now velocity inmgral MV = mean flow velocity (cmhl : PAP intracoronary papaverine 110 mgt : PV = peak phasic flow velocity (am(s): other abbreviations as in Table 2 .
Coronary Flow Velocity Responses (Table 4) Adenosine infusion. In group I , adenosine infusions of50 . Tables 2 and 3 . Coronary Vasodilator Reseroe Ratios (Table 5) Adenosine infusion versus papaverine ( Fig . 3 and 4) . The coronary vasodilator reserve ratio in group I for adenosine (50. 100 and 150 gglkg) was 1 .67 t I .D), 2 .51 ± 0 .94 and 2 .94 ± 1 .50, respectively ; for papaverine, it was 2 .94 t 1 .00 .
In group 2 . the ratio was 1 .09 t 0 . .Adenosine bolus (Fig. 5) . The coronary vasodilator re serve ratio for a 2.5 mg bolus injection of adenosine was 2 .17 t 0 .91, which was less than that after papaverine that after both papaverine and the continuous adenosine infusion 1100 tuglkg per min) . .A reduced (<2 .5) coronary reserve ratio saggesrive of rnicrocircalatorv abnormalities was present in six patients in group 1 . During adenosine infusion, chest pain or fullness was reported in 9 of 17 patients in group I and 7 of 17 patients in group 2 . Adenosine was associated with new ST segment depression in four and five patients in groups I and 2, respectively .
Coronary angiographic responses . Hyperemia during adenosine infusion did not increase the absolute angio graphic coronary luminal diameter in either group of pa tients . There was no increase in the proximal epicardial vessel diameter (control 3 .72 0 0.991o 3 .72 ± 0 .86 mm after adenosine ; percent change I ± 6%0) compared with the and and distal segments (3 .39' 0 .85 vs . 3 .35 ' 0 .98 mm ; percent change 1 ± 12%) during adenosine infusion . ECG responses to adenosine and papaverine (Fig . 6) . Papaverine, but not adenosine, increased the QTc interval (445 ± 44 to 501 ± 43 ms after papaverine ; p < 0 .01 vs . baseline and p < 0.05 vs. adenosine ; 462' 61 to 455 ± 47 ms after maximal adenosine ; p = NS) . There were no significant alterations in PR, QRS or RR intervals with either agent . Figure 6 shows the hemodynamic and flow velocity signals typically obtained during adenosine and papaverine admin istration in the same patient . Adenosine produced no ECG changes, whereas papaverine increased the QTc interval and induced brief nonsustained runs of ventricular tachycardia in one patient in group 2 . Transient (<2 s pauses) sets nd degree heart block oc curred in four patients recei .ing 150 pglkg per min of adenosine and one patient with a 2 .5 mg bolus injection (Fig.  7) . These brief periods spontaneously resolved arid did not recur before cessation of the adenosine infusion . No patient required atropine or temporary pacing or had a complication requiring premature study termination.
Discussion
Coronary flow velocity responses to intravenous adenosine . Adenosine has been widely used in studies of the coronary circulation in animals . Until recently, its safety and dose response characteristics in patients, especially those with coronary artery disease, have not been defined . The current study confirms a dose range for continuous intravenous infusions and demonstrates that low dose bolus administra tion effectively produces increases in coronary blood flow Adenosine as an alternative to papaverine . The ultrashort blood half life of adenosine results in complete disappear ance of hyperemic effects and drug associated sensations within minutes of termination of infusion . Serious complica tions found with papaverine should therefore never develop . Although transient heart block was observed at the highest doses in four patients, adenosine did not cause significant alteration of ECG intervals . The episodes of heart block were usually <2 s in duration, sporadic and immediately (<45 s) abolished with termination of infusion . Papaverine caused consistent QT prolongation and one episode of ventricular tachycardia . These findings, confirmed by others (5 8) and especially prominent in women with a slow heart Limitations to the use of intravenous adenosine may occur in patients with bronchospastic pulmonary disease or those with arterial hypotension or high degree atrioventric ular (AV) block . Adenosine may also be contraindicated in patients with sick sinus syndrome because of potential production of symptomatic bradycardia. Concomitant use of dipyridamole may markedly potentiate the effects of adeno sine and may precipitate severe hypolension or advanced conduction delay (11 13,19,20) . Hyperemic responses may be blunted in patients receiving theophylline, which blocks adenosine receptors (20) .
Adenosine as an alternative to dpyridamole. Pharmaco logic coronary vasodilation is used with myocardial scintig raphy to evaluate the presence and prognostic significance of coronary artery disease (21, 22) . Dipyridamole has been a commonly used agent, increasing coronary blood flow by blocking cellular uptake of adenosine (23) . Adenosine is an effective alternative agent to dipyridamole (19, 24) , with a significantly shorter onset and offset of action . Vernal et al . (19) performed thallium scintigraphy with intravenous aden osine (50 to 140 µg/kg per min) in 89 patients and indicated that the overall sensitivity and specificity for detection of coronary artery disease were 83% and 94%, respectively . Despite a high incidence of short lived side effects (occurring Figure 7 . Date recorded after a 2 .5 mg halos injection of adenosine . Adenosine is given through a femoral vein fat The hterk mark) and hyperemia is observed within IS s recording speed is increased fruits 10 minis at left to 100 minis at right) . Transient heart block is seen before peak hyperemic effect . This example was a worst case demonstration of bean block after low dose bolus adenosine administration . IV = inirave . nous : other abbreviations as in Figure 6 , in 83% of patients), adenosine induced hyperemia for use with thallium scintigraphy appeared to be a safe and poten tially useful test in patients unable to exercise (19) . The frequency of chest pain and other nonspecific symptoms appeared higher with adenosine than with dipyridamole (25) . but the symptoms were more rapidly dissipated after cessa tion of drug infusion. Adenosine also appears to be a more potent coronary vasodilator than dipyridamole (24) .
Chest pain and adenosine induced hyperemia. Chest pain was a frequent finding in patients with or without coronary artery disease, but characteristic changes of ischemia as sessed with the 12 lead ECG or pulmonary artery diastolic pressure measurements did not occur in a consistent man ner. Chest pain resembling angina pectoris, commonly re ported in most studies with intravenous adenosine infusions (10 14,26,27) , appears in a dose dependent manner (13) . At very high doses (>200 pg/kg), episodes of first and second degree AV block preceded the onset of chest pain (13) . Adenosine induced coronary vasodilation is mediated pre dominantly by the P, purinergic receptor subtype (20) , with inhibition of the slow calcium inward current or activation of adenylate cyclase in A, receptors in vascular smooth muscle (28) . However, the specific pharmacologic role in regulating coronary blood flow remains under study (20) . Intracoronary adenosine (in doses of I0 s . l0 z and 10 r' mot/liter for periods of 2 min) provoked typical anginal chest pain not elicited during systemic adenosine infusion (14). Aminophyl line, an adenosine P, receptor antagonist 1291 . reduced the severity of both adenosine and exercise induced chest pain (14). indicating that adenosine produced cardiac pain through receptors that could be partly blocked by amino phylline and other mcthylxanthines blocking adenosine re ceptors .
Duration of intravenous adenosine effects . In the current stud, ,intravenous adenosine increased coronary blood flow velocity to its maximum (within 10%; of the papaverine response) by 20' 25 s, with a return to baseline by 45 ± 20 s after discontinuation. These results differed somewhat from earlier reports (10) , most likely because of the different sites and methods of infusion . A submaximal increase in blood flow at doses >150 Aglkg per min ws observed in one patient in our study and in 8% of the patients studied by The coronary vasodilator reserve ratio had a weaker although significant correlation compared with mean flow velocity response for several reasons . First, small changes in baseline or hyperemia values, or both, have an important effect when using a ratio calculation . Second, the range of coronary vasodilator reserve values was narrower than mean flow velocity . making a greater statistical correlation more difficult to obtain. When using a coronary vasodilator reserve ratio >2 .5 as a lower limit of normal, five and four patients would have had an abnormally low coronary vaso dilator reserve with adenosine and papaverine, respectively . The normal coronary vasodilator reserve ratio was lower in the current study than that reported by Wilson et ai . (10) . This difference has been observed by others (6, 7) and in earlier studies in our own laboratory (U 17), a finding attributed to the techniques of flow velocity measurement and possibly inclusion of more patients who may have microcirculatory abnormalities (for example, hypertension or left ventricular hypertrophy) .
Although 12 to 14 mg doses of papaverine have been suggested as optimal (3), 10 mg of papaverine has been the most commonly used dose to achieve maximal vasodilation in studies applying these techniques (34). The highest range of tolerable effects of adenosine in healthy volunteers was observed after 140 to 200 pug/kg per min (11, 26, 27 Technical problems influencing the accuracy of carouarv flaw velocity hare been described in detail elsewhere (1 .3,33,34 ) . Errors in Doppler velocity measurements are related to the shape of the velocity profile, the angle of incidence and position of the sample volume and should be minimal in our patients with the stable proximal location of the Doppler catheter. Only coronary flow velocity signals with clearly demarcated systolic and diastolic phasic wave forms were accepted for analysis . Previous studies have demonstrated the linear relation between flow velocity and measured coronary blood flow (3, 15) , as well as the high correlation between subselective and nonselective coronary Doppler flow velocities (15 .35) in patients without coronary artery disease. Because of remote risk of vessel closure, subselective velocity measurements were not performed in group 2 patients. Left main coronary artery blood flow velocity did indicate the proximal velocity responses and, therefore, reliably reflected comparative effects of papaver ine and adenosine in this study.
Clinical significance . In most patients, intravenous aden osine infusion in doses >100 yuglkg per min and low dose (2.5 mg) bolus injection produces coronary hyperemia nearly equivalent to that after intracoronary papaverine without significant QTc prolongation or propensity for serious ven tricular arrhythmia. This ultrashort acting agent safely pro vides an alternative for pharmacologic induction of maximal coronary hyperemia for studies of the coronary circulation in patients with or without coronary artery disease .
